Is Bayer CropSci. overvalued or undervalued?

As of 4 September 2025, Bayer CropSci. has moved from a valuation grade of very expensive to expensive. The company is currently considered overvalued based on its key metrics. The PE ratio stands at 38.78, while the Price to Book Value is 8.06, and the EV to EBITDA ratio is 30.48. These figures indicate a premium valuation compared to peers.
In comparison to its industry counterparts, Bayer's PE ratio is higher than P I Industries at 35.21 and UPL at 34.82, both of which are in a more attractive valuation range. Additionally, Bayer's PEG ratio is notably at 0.00, suggesting no expected growth, which further complicates its valuation outlook. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -7.82% compared to the Sensex's 3.30%, reinforcing the notion that Bayer CropSci. is overvalued in the current market environment.